Evidence map›Paper›PMID 34510104›Full record

Trial reportMedical care2021

Heterogeneity of Treatment Effects Among Patients With Type 2 Diabetes and Elevated Body Mass Index in a Study Comparing Group Medical Visits Focused on Weight Management and Medication Intensification.

Elizabeth A Kobe, Matthew J Crowley, Amy S Jeffreys, William S Yancy, Jennifer Zervakis, David Edelman, Corrine I Voils, Matthew L Maciejewski, Cynthia J Coffman

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Medical care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Elizabeth A KobeDuke University School of Medicine.
Matthew J CrowleyDurham Veterans Affairs Center of Innovation to Accelerate Discovery and Practice Change (ADAPT).
Amy S JeffreysDurham Veterans Affairs Center of Innovation to Accelerate Discovery and Practice Change (ADAPT).
William S YancyDuke University School of Medicine.
Jennifer ZervakisDurham Veterans Affairs Center of Innovation to Accelerate Discovery and Practice Change (ADAPT).
David EdelmanDurham Veterans Affairs Center of Innovation to Accelerate Discovery and Practice Change (ADAPT).
Corrine I VoilsWilliam S Middleton Memorial Veterans Hospital.
Matthew L MaciejewskiDuke University School of Medicine.
Cynthia J CoffmanDurham Veterans Affairs Center of Innovation to Accelerate Discovery and Practice Change (ADAPT).
Duke Medical Center · USDuke University · USUniversity of Wisconsin–Madison · US

Funding

NRSA Training CoreTL1TR002555 · NCATS · DUKE UNIVERSITY · PI EDELMAN, DAVID · 2018 to 2022
$3.7M
HSRD VA CIN 13-410NCATS NIH HHS TL1 TR002555
6 · The paper itself

Abstract

backgroundIlluminating heterogeneity of treatment effect (HTE) within trials is important for identifying target populations for implementation.

objectiveThe aim of this study was to examine HTE in a trial of group medical visits (GMVs) for patients with type 2 diabetes and elevated body mass index. RESEARCH DESIGN AND MEASURES: Participants (n=263) were randomized to GMV-based medication management plus low carbohydrate diet-focused weight management (WM/GMV; n=127) or GMV-based medication management alone (GMV; n=136) for diabetes control. We used QUalitative INteraction Trees, a tree-based clustering method, to identify subgroups with greater improvement in hemoglobin A1c (HbA1c) and weight from either WM/GMV or GMV. Subgroup predictors included 32 baseline demographic, clinical, and psychosocial factors. Internal validation was conducted to estimate bias in the range of mean outcome differences between arms.

resultsQUalitative INteraction Trees analyses indicated that for patients who had not previously attempted weight loss, WM/GMV resulted in better glycemic control than GMV (mean difference in HbA1c improvement=1.48%). For patients who had previously attempted weight loss and had lower cholesterol and blood urea nitrogen, GMV was better than WM/GMV (mean difference in HbA1c improvement=1.51%). No treatment-subgroup effects were identified for weight. Internal validation resulted in moderate corrections in mean HbA1c differences between arms; however, differences remained in the clinically significant range.

conclusionThis work represents a novel step toward targeting care approaches for patients to maximize benefit based on individual patient characteristics.

Indexed as

Body Mass IndexGroup ProcessesOffice VisitsWeight LossDiabetes Mellitus, Type 2HumansHypoglycemic AgentsHypoglycemic Agents

Identifiers

PMID34510104
PMCPMC8516740
OpenAlexW3199423498

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.